ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
03. April 2024 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...
ObsEva Announces Update on Board of Directors
19. März 2024 02:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
28. Februar 2024 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
Geneva Court Grants Temporary Moratorium to ObsEva
31. Januar 2024 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
30. November 2023 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
Organon Returns Ebopiprant to XOMA
27. Oktober 2023 17:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
ObsEva Files half Year 2023 Financial Statements
27. September 2023 01:00 ET
|
ObsEva SA
ObsEva Files half Year 2023 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 – ObsEva SA (SIX: OBSN), a...
ObsEva Recovers Full Worldwide Rights on Nolasiban
13. Juli 2023 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – July 13, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023
30. Juni 2023 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
Annual General Meeting 2023
08. Juni 2023 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...